Breakthrough Technology. Grounded Application. Measurable Outcomes.
nVector provides cutting edge CNS based gene therapies, designer AAV capsids to target specific cell types, clinical grade biomarker assays, and the development of new biomarker assays to accelerate your existing projects and quick-launch new initiatives. Our patented GreenGlia Technology enables us to access cells never before targeted, such as microglia, the brain immune cells, and neurons by cell type. The nVector offering includes both fully formed solutions, and the capability to customize to your unique specifications.
nVector’s innovation is rooted in breakthrough work conducted at leading research institutions around the country. These include the world-renowned Adeno-Associated Virus development conducted at the University of Florida, as well as central nervous system research at the University of Pittsburgh and the Barrow Neurological Institute, the world’s largest neurological disease treatment and research center.
The first company to emerge with a market-ready product offering was Iron Horse Diagnostics, a leader in ALS diagnostics. Now nVector is extending that scope with cutting edge capabilities that help revolutionize the treatment of any CNS disease.
Robert Bowser, PhD
Chairman of the Board
Dr. Bowser is an internationally recognized leader in exploring the mechanisms underlying neurodegeneration. He has published over 200 articles in peer-reviewed journals and has received numerous grants from organizations including the National Institutes of Health (NIH), the Department of Defense, Target ALS, and the ALS Association (ALSA)
A Professor of Neurology and Translational Neuroscience, and Chief Scientific Officer at the Barrow Neurological Institute and St. Joseph’s Hospital and Medical Center in Phoenix, Arizona, Dr. Bowser is also Director of the Gregory W. Fulton ALS Research Center at the Barrow Neurological Institute.
Dr. Bowser was co-Founder of Knopp Biosciences, a drug development company located in Pittsburgh, PA, and has consulted for a number of pharmaceutical and biotechnology companies. He earned his B.S. in Biological Sciences from Carnegie Mellon University and Ph.D. in Cell Biology from Yale University.
Fredric Manfredsson, PhD
Chief Science Officer
Fredric Manfredsson, PhD, is an associate professor in the Department of Translational Neuroscience at Barrow Neurological Institute. Dr. Manfredsson’s expertise includes gene therapy for Parkinson’s disease and other neurodegenerative diseases. Dr. Manfredsson’s research has focused on understanding the role of the protein alpha-synuclein in both healthy cells and those affected by Parkinson’s disease. His research also emphasizes understanding the symptomology of the disease, with a focus on the treatment of levodopa-induced dyskinesia and nonmotor symptoms experienced by nearly all patients with Parkinson’s disease.
Dr. Manfredsson’s is Chair of the American Society for Gene & Cell Therapy Neurological & Ophthalmological Committee, and Past President of The American Society for Neural Therapy and Repair, and the Society for Neuroscience. Dr. Manfredsson earned his doctorate degree in neuroscience from the University of Florida in Gainesville, where he also completed a postdoctoral fellowship in neuroscience.
Ivette Sandoval, PhD
VP of Vector Development
Ivette Sandoval, PhD, is an associate professor in the Department of Translational Neuroscience at Barrow Neurological Institute. Dr. Sandoval started her gene therapy career in ophthalmology and has since transitioned to neurodegenerative diseases, and the role of inflammatory cells in disease progression. Dr. Sandoval’s research laid the foundation for nVector’s initial GreenGlia library, and is currently working on new iterations of this AAV library.
Dr. Sandoval received her PhD from Baylor College of Medicine in Houston, Texas, and did her postdoctoral training at Michigan State University.
Michael Hull, MBA
Mr. Hull has extensive experience in financial, operational support and commercializing discoveries for start-ups. He co-founded InVent Life Sciences, a commercialization company focused on life science discoveries and worked with numerous research institutions and small businesses on obtaining small business grants for further validation studies on the path to commercialization. He has vast experience in building operations to scale for technology companies and working with research teams to commercialize their discoveries.
Gerry Shaw, PhD,
Co-Founder and Scientific Advisor
Dr. Shaw was Professor of Neurosciences at the University of Florida and has performed research on the cytoskeleton for the past 25 years. Dr. Shaw is also Founder and President of EnCor Biotechnology Inc., a company that specializes in the generation of antibodies. EnCor will provide Iron Horse antibodies for use in all products, with exclusive license for use of EnCor antibodies in clinical diagnostic assays.
Ms. An has over 25 years experience in assay development and clinical assay lab management. Prior to working at nVector and Iron Horse Diagnostics, she worked at the University of Pittsburgh Proteomics Core Lab facility, PPD, and Sequel Genetics. She is also currently a part-time laboratory technician at the Barrow Neurological Institute.